Alvotech (Nasdaq: ALVO) and an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) have announced a settlement and license agreement with Johnson & Johnson (NYSE: JNJ) concerning AVT04, Alvotech's proposed biosimilar to Stelara (ustekinumab) in the U.S. 

As per the settlement agreement, subject to regulatory approval, AVT04 can be marketed in the U.S. no later than February 21, 2025. It is important to note that AVT04 is still an investigational product, pending regulatory approval, and its biosimilarity has not yet been established by authorities.

In pre-market, $TEVA is trading at $7.44, up $0.11  (+1.50%), while $ALVO stands at $8.15.

Teck Resources Limited (NYSE: TECK) provided an update on its engagement with parties that have expressed interest in potential transactions involving its steelmaking coal business. 

The company's Board of Directors and independent Special Committee are diligently evaluating all actionable proposals received, aiming to determine the best course of action in the interests of Teck's shareholders and stakeholders. 

In this ongoing review, Teck has confirmed its engagement with Glencore plc (OTCMKTS: GLNCY) regarding a preliminary, conditional, and non-binding proposal related to the steelmaking coal business. 

$TECK is trading at $42.96, indicating a pre-market increase of $0.45 (+1.06%)

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)